1. Lindholm L.H., Ibsen T., Dahlof B. Et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet 2002; 359; 1004-1010.
2. Zanchetti A., Bond G., Hennig M, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 42272427.
3. Dahlof B., Sever P.S., Poulter N.R, et al. Prevention of cardiovascularevents with an antihypertensive regimen of amlodipine addingperindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
4. Lithell H., Pollare T., Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992;.1:92-101.
5. Рекомендации пo профилактике, диагностики и лечению артериальной гипертензии. Артериальная гипертензия 2001 том 7. приложение 1.
6. Lindholm L.H., Carlberg В., Samuelsson О. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366: 1545-53.
7. Kaplan N.K., Opie L.N. Controversies in hypertension The Lancet 2006; 367:168-176
8. Irvine N.A., Lipworth B.J., McDevitt D.G. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol. 1990 ;30:119-26
9. Djian, J Clinical evaluation of betaxolol as a once-daily treatment for hypertension in 4685 patients Br J Clm Pract 1985;39:188-191.
10. Бытрова M.M., Бриттов A.H., Горбунов Ю.М. с соавторами. Лечение артериальной гипертензии бетаксололом у женщин в постменопаузе. Терапевтический архив.1999;71(6):67-69.
11. Jaillard J., Rouffy J., Sauvanet J. et al/ Long-term influence of betaxolol on plasma lipids and lipoproteins. In Morselli et al. L.E.R.S.Monograph. New York, Raven Press; 1983; 221-231.
12. Van Os, Van Brummeneisen P., Woitteis A.J.J. Betaxolol on obese hypertensive patients Long-term effects on blood pressure and serum lipids. Neth J Med 1991; 40:227-231.
13. Hamon P., Bellemin J.P., Cressens J.P. et al. Responses mataboliqies et endocriniennes a l“hyperglycemie et a l“hyperglycemie aiguë chez le volontaire sain recevant du betaxolol. J Am Med Assoc (French edn) 1985 ; 10 Suppl. 99 : 37-40.
14. Davies I., Larribaut J., Thiercelin J. et al. Betaxolol does not modify hypoglycemic actions on glibenclamide or metformine in normal subjects. Br J Clin Pharmacol 1984; 17:622P.
15. Brugmann U., Blassini R., Rudolph W. et al. Comparative effects of long-acting beta-adrenergic receptor blockers with and without cardioselectivity: double-blind randomized cross-over and placebo-controlled study of betaxolol and nadolol. Circulation 1983; 68:Suppl 111:406.
16. Kilborn J.R., Morseli P.L., Sauders J. et al. The effects of new beta-blocker SL 75212 on the cardiovascular responses to insulin induced hypoglycemia in man. Br J Clin Pharmacol 1979; 8:409P.
17. Johnson B.F., Whelton A. A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive Drugs. Am J Ther. 1994;1:260-267
18. Lee J.Y., Kusek J.W., Greene P.G., et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. AmJ Hypertens 1996; 9: 719-725.
19. Hosie J., Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens 1995; 9:S15-S18.
20. Kunka R.L., Wong Y.Y., Andersen R.L., Haack D.G. Steady-state fluctuation and variability of betaxolol and atenolol plasma levels. Ther Drug Monit. 1989 Sep;11(5):523-7
21. Dabrowski R., Wozniak J., Kowalik I., Szwed H.Working women are better responders to beta-blocker monotherapy of mild hypertension than men. Int J Clin Pharmacol Res. 2004; 24(4): 123-128.
22. Takase B., Abe Y., Nagata M. et al. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother. 2005 Oct;59 Suppl 1.S158-62
23. Kobayashi N., Yoshida K., Mita S. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens. 2004 Jul;22(7):1397-402.
